In the latest trading session, ABT posted a 1.82% gain compared with a 0.65% rise in the S&P 500, marking its strongest relative performance in four weeks. Volume surged by 25% above its 30-day average, indicating heightened investor interest. Analysts attribute the move to renewed optimism around the company’s high-growth medical device division and anticipation of upcoming quarterly results.

Abbott will release its fourth-quarter 2025 results before markets open on January 22, followed by a live webcast of the conference call at 9:00 a.m. Eastern. Management is expected to discuss diagnostic segment revenue growth of approximately 8% year-over-year and margin expansion targets driven by cost-efficiency programs. The webcast and an archived replay will be available on the company’s investor relations website.

At CES® 2026, Abbott unveiled Libre Assist, an AI-driven feature within its Libre app that offers real-time guidance on how meal choices will impact glucose levels. The tool uses generative AI to predict glucose response, displays a color-coded risk rating, and leverages data from the FreeStyle Libre continuous glucose monitoring system to confirm outcomes. Investors view this enhancement as a catalyst for accelerating CGM adoption and increasing recurring revenue from digital services.

Evercore ISI raised its price target on ABT to $144, implying roughly 16% upside from current levels. The firm highlighted the potential for Libre Assist to drive incremental sales in the diabetes care franchise and strengthen market share against peers such as Johnson & Johnson and Medtronic. With a market capitalization near $216 billion and expected low-single-digit revenue growth across diagnostic and nutrition segments, analysts forecast sustained free cash flow generation to support dividend increases and share repurchases.